Table 5.
Association of clinical and serum predictors, and report of severe side effects from tamoxifen
| Clinical and serum predictors | Number of participants taking tamoxifen (N = 241)
|
|
|---|---|---|
| Report of severe side effects
a | ||
| Unadjusted | Adjusted a | |
| OR (95% CI) P value | OR (95% CI) P value | |
| Age | ||
| Age ≤ 40 | - | - |
| Age 41 – 50 | 1.14 (0.38, 3.34) 0.81 | 0.59 (0.05, 5.95) 0.65 |
| Age 51 – 60 | 2.16 (0.63, 7.44) 0.21 | 1.34 (0.11, 15.93) 0.81 |
| Age 61 – 70 | 1.0 (0.28, 3.54) 1.0 | 0.04 (0.001, 1.13) 0.06 |
| Age > 70 | 0.56 (0.11, 2.78) 0.48 | 0.08 (0.003, 1.89) 0.11 |
| Body mass index (BMI) | 1.06 (0.96, 1.17) 0.23 | 0.99 (0.82, 1.18) 0.92 |
| Ethnicity | ||
| Caucasian | - | - |
| Latina/Hispanic | 2.0 (0.44, 9.02) 0.36 | 23.98 (0.50, 1146.26) 0.11 |
| Black/AA | 2.41 (0.20, 27.75) 0.48 | 40.80 (0.51, 3213.88) 0.09 |
| Asian/East Asian | 0.54 (0.21, 1.34) 0.18 | 0.58 (0.13, 2.48) 0.46 |
| Education | 0.61 (0.27, 1.38) 0.24 | 1.62 (0.42, 6.19) 0.48 |
| Previously used post-menopausal hormone therapy (HT) | 1.69 (0.71, 4.03) 0.23 | 16.16 (1.42, 183.28) 0.02 |
| Months on tamoxifen | 0.78 (0.57, 1.05) 0.10 | 0.79 (0.48, 1.29) 0.35 |
| ≤ 12 months | - | - |
| 13 – 24 months | 0.44 (0.14, 1.34) 0.15 | 0.05 (0.005, 0.58) 0.01 |
| 25 – 36 months | 0.09 (0.01, 0.46) 0.004 | 0.03 (0.004, 0.38) 0.006 |
| > 36 months | 0.60 (0.24, 1.47) 0.26 | 0.35 (0.07, 1.75) 0.20 |
| Endoxifen levelsb | 1.54 (0.99, 2.40) 0.05 | 1.79 (0.90, 3.56) 0.09 |
N number of participants; OR odds ratios; CI confidence interval; P value ≤ 0.05; AA African American
a
Odd ratios adjusted for age, BMI, ethnicity, level of education, prior post-menopausal hormone therapy use, tamoxifen length (in months) and endoxifen levels
b
Odd ratio for endoxifen levels rescaled to the standard deviation